$17.95
1.05% yesterday
Nasdaq, May 01, 10:00 pm CET
ISIN
JE00BYSS4X48
Symbol
NVCR

Novocure Ltd. Stock price

$17.95
+0.43 2.45% 1M
+1.77 10.94% 6M
-11.85 39.77% YTD
+5.21 40.89% 1Y
-63.42 77.94% 3Y
-42.53 70.32% 5Y
-0.33 1.81% 10Y
Nasdaq, Closing price Thu, May 01 2025
-0.19 1.05%
ISIN
JE00BYSS4X48
Symbol
NVCR
Sector

Key metrics

Market capitalization $2.00b
Enterprise Value $1.77b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.84
P/S ratio (TTM) P/S ratio 3.22
P/B ratio (TTM) P/B ratio 5.53
Revenue growth (TTM) Revenue growth 18.27%
Revenue (TTM) Revenue $621.71m
EBIT (operating result TTM) EBIT $-165.91m
Free Cash Flow (TTM) Free Cash Flow $-72.14m
Cash position $931.28m
EPS (TTM) EPS $-1.51
P/E forward negative
P/S forward 3.20
EV/Sales forward 2.83
Short interest 7.29%
Show more

Is Novocure Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,788 stocks worldwide.

Novocure Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Novocure Ltd. forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Novocure Ltd. forecast:

Buy
71%
Hold
29%

Financial data from Novocure Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
622 622
18% 18%
100%
- Direct Costs 141 141
7% 7%
23%
481 481
22% 22%
77%
- Selling and Administrative Expenses 423 423
13% 13%
68%
- Research and Development Expense 212 212
0% 0%
34%
-154 -154
21% 21%
-25%
- Depreciation and Amortization 12 12
6% 6%
2%
EBIT (Operating Income) EBIT -166 -166
19% 19%
-27%
Net Profit -164 -164
15% 15%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Novocure Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novocure Ltd. Stock News

Positive
The Motley Fool
6 days ago
Shares of NovoCure (NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m.
Positive
The Motley Fool
7 days ago
Thursday morning NovoCure (NVCR 4.28%) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess of 4%, easily topping the slightly over 2% increase of the S&P 500 index.
Neutral
Seeking Alpha
8 days ago
NovoCure Limited (NASDAQ:NVCR ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Executive Chairman Ashley Cordova - CEO Christoph Brackmann - CFO Frank Leonard - EVP and President, NovoCure Oncology Nicolas Leupin - CMO Conference Call Participants Larry Biegelsen - Wells Fargo Jason Bednar - Piper Sandler Vijay Kumar - Evercore ...
More Novocure Ltd. News

Company Profile

NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Head office Jersey
CEO Ashley Cordova
Employees 1,488
Founded 2000
Website www.novocure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today